| Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch: A Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease. | |
| | |
MedLine Citation:
|
PMID: 20975519 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The rationale for the development of the rivastigmine transdermal patch was to improve upon an efficacious therapy by mitigating certain adverse events, such as nausea and vomiting. This may be particularly important in Alzheimer disease patients with low body weights, who may be more susceptible to these adverse events. This analysis compared the effect of body weight on tolerability in Alzheimer disease patients receiving rivastigmine capsules or rivastigmine patch. Using data from a 24-week trial, adverse events and discontinuations were evaluated in patients stratified on the basis of extreme low weight (<50 kg), medium weight (50 to 80 kg), and high weight (>80 kg) at baseline. Rivastigmine patch was generally well tolerated, regardless of patient body weight. Among patients receiving rivastigmine patch, lower body weight, as stratified, was not associated with a higher adverse event rate; however, there was an association between a higher adverse event rate and low body weight among patients receiving rivastigmine capsules. Discontinuations because of adverse events were not directly related to weight. A lower incidence of adverse events was apparent with transdermal delivery of rivastigmine compared with oral administration. |
| | |
Authors:
|
Jae-Hong Lee; Jeff Sevigny |
Related Documents
:
|
2291429 - Anorexia/bulimia nervosa: the development of anorexia nervosa and of mental symptoms. t... 21773889 - Clinical impact of combined transplantation of autologous skeletal myoblasts and bone m... 7055399 - Caloric requirements in patients with inflammatory bowel disease. 2737169 - A controlled trial of sip-feed supplements in elderly orthopaedic patients. 8598429 - Enteral nutritional support in acute alcoholic pancreatitis. 21594379 - Molecular analysis of lymphoid malignancies. 8551439 - Photorefractive keratectomy in pediatric patients. 12605259 - Level of glucocorticoid receptor mrna expression in iris tissue and postoperative ocula... 8321759 - Successful treatment for phantom pain. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Alzheimer disease and associated disorders Volume: 25 ISSN: 1546-4156 ISO Abbreviation: Alzheimer Dis Assoc Disord Publication Date: 2011 Jan-Mar |
Date Detail:
|
Created Date: 2011-02-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704771 Medline TA: Alzheimer Dis Assoc Disord Country: United States |
Other Details:
|
Languages: eng Pagination: 58-62 Citation Subset: IM |
Affiliation:
|
*Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea †Novartis Pharmaceuticals Corporation, East Hanover, NJ. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between thyroid hormone levels and regional cerebral blood flow in Alzheimer disease.
Next Document: Direct medical costs in patients with fibromyalgia: Cost of illness and impact of a brief multidisci...